LB/CV-N AND RC101 PRIMATE TESTING

LB/CV-N 和 RC101 灵长类动物测试

• 批准号: 8172743
• 负责人: DOROTHY L PATTON
• 金额: $ 46.53万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172743
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Drug Formulations; Environment; Funding; Grant; HIV; Institution; Laboratories; Local Microbicides; Macaca; Modeling; Peptides; Population; Primates; Research; Research Personnel; Resources; Safety; Source; Toxic effect; United States National Institutes of Health; Vagina; in vitro Assay; in vivo; inhibitor/antagonist; novel; pathogen; prevent; rectal; research study; transmission process; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Drug Formulations; Environment; Funding; Grant; HIV; Institution; Laboratories; Local Microbicides; Macaca; Modeling; Peptides; Population; Primates; Research; Research Personnel; Resources; Safety; Source; Toxic effect; United States National Institutes of Health; Vagina; in vitro Assay; in vivo; inhibitor/antagonist; novel; pathogen; prevent; rectal; research study; transmission process

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In order to prevent the ongoing spread of HIV and other STDs, it is imperative that an effective topical microbicide product be developed and made available for use. This project proposes to develop a combination topical microbicide product, targeted primarily at preventing the transmission of HIV, and also have activity in preventing other STDs. The product will be made up of novel compounds (a peptide and a fusion inhibitor) which exert synergistic effects on one another, thereby attacking pathogens from as many angles as possible, while preserving the integrity and microflora populations of the rectal and vaginal environments. Product formulation is guided by iterative safety, toxicity and efficacy assays (in vitro, ex vivo and in vivo). Our macaque model is used to determine the most feasible and effective delivery mechanisms, compound availability and product safety. These experiments in the macaque model are essential in filling the gap between laboratory and clinical studies.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 为了防止艾滋病毒和其他性传播疾病的持续传播，必须开发有效的局部杀菌剂产品并可以使用。该项目提议开发一种组合局部杀菌剂产品，主要旨在防止HIV传播，并且还具有预防其他性病的活性。该产品将由新型化合物（一种肽和融合抑制剂）组成，它们相互发挥协同作用，从而从尽可能多的角度攻击病原体，同时保留直肠和阴道环境的完整性和菌群种群。 产品配方由迭代安全性，毒性和有效性测定（在体外，体内和体内）进行指导。我们的猕猴模型用于确定最可行，最有效的输送机制，复合可用性和产品安全性。猕猴模型中的这些实验对于填补实验室和临床研究之间的差距至关重要。